Mabwell

Shanghai, China, September 4, 2026 Mabwell (Shanghai) Bioscience Co., Ltd. has announced Phase Ib/IIa clinical results for its investigational...

SHANGHAI, June 23, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND)...

RANCHO CORDOVA, Calif., June 18, 2026 SK pharmteco, a leading global contract development and manufacturing organization (CDMO), has announced...

SOUTH SAN FRANCISCO, Calif., June 17, 2026 Genentech, a member of the Roche Group, has reached a significant regulatory...

COPENHAGEN, Denmark, June 18, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, has unveiled encouraging...

SHANGHAI, China, June 5, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug...

CHENGDU, China, 21 May 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that two registrational studies involving its lead oncology...

SHANGHAI, China, 22 May 2026 Mabwell announced that new clinical data for its investigational Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821...

SHANGHAI, China, May 20, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has approved the supplemental application...

SAN DIEGO, May 7, 2026 Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to...